Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

December 15, 2025

Study Completion Date

December 31, 2026

Conditions

Non-small Cell Lung CancerEGFR Activating MutationCell Cycle DeregulationEGFR-TKI Resistant Mutation

Interventions

DRUG

Osimertinib plus Dalpiciclib

osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle

Trial Locations (1)

RECRUITING

Department of Thoracic Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER